Results 21 to 30 of about 83,483 (295)

Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB. [PDF]

open access: yes, 2016
Repurposing has gained momentum globally and become an alternative avenue for drug discovery because of its better success rate, and reduced cost, time and issues related to safety than the conventional drug discovery process.
Brindha, Sridharan   +4 more
core   +1 more source

Buying time: Drug repurposing to treat the host in COVID‐19H

open access: yesPharmacology Research & Perspectives, 2020
In 2016 Fedson stated …. “For almost two decades, leading scientists and health officials have warned that we must prepare for a potentially devastating global pandemic of an infectious disease. Initial concern was focused on …H5N1….
Jennifer H. Martin   +2 more
doaj   +1 more source

Synergistic drug combinations from electronic health records and gene expression. [PDF]

open access: yes, 2016
ObjectiveUsing electronic health records (EHRs) and biomolecular data, we sought to discover drug pairs with synergistic repurposing potential. EHRs provide real-world treatment and outcome patterns, while complementary biomolecular data, including ...
Chen, William   +19 more
core   +2 more sources

A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma

open access: yesClinical Epigenetics, 2023
Background N-methyl-2-pyrrolidone (NMP) is an epigenetically active chemical fragment and organic solvent with numerous applications including use as a drug-delivery vehicle. Previously considered biologically inert, NMP demonstrates immunomodulatory and
Jake Shortt   +8 more
doaj   +1 more source

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. [PDF]

open access: yes, 2018
The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes.
Aftab, Blake T   +13 more
core   +2 more sources

In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. [PDF]

open access: yes, 2016
The long-term overall survival of Ewing sarcoma (EWS) patients remains poor; less than 30% of patients with metastatic or recurrent disease survive despite aggressive combinations of chemotherapy, radiation and surgery.
Alturkmani, Hani   +11 more
core   +3 more sources

The benefits of in silico modeling to identify possible small-molecule drugs and their off-target interactions [PDF]

open access: yes, 2018
Accepted for publication in a future issue of Future Medicinal Chemistry.The research into the use of small molecules as drugs continues to be a key driver in the development of molecular databases, computer-aided drug design software and collaborative ...
Blomberg N   +6 more
core   +2 more sources

A brief overview of current drug repurposing approaches for COVID-19 management [PDF]

open access: yes, 2020
This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19).
Rodrigues, Pedro da Fonseca Soares   +1 more
core   +2 more sources

Drug Repurposing

open access: yes
Citation: 'drug repurposing' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.12648 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
Phil Ambery   +2 more
  +6 more sources

Repurposing drugs to target nonalcoholic steatohepatitis [PDF]

open access: yes, 2019
Nonalcoholic fatty liver disease (NAFLD) is a complex disorder that has evolved in recent years as the leading global cause of chronic liver damage.
Pirola, Carlos José   +1 more
core   +1 more source

Home - About - Disclaimer - Privacy